CGRP Forum is made possible thanks to support from AbbVie, Lilly, Organon and Pfizer, all of whom have no influence or control of editorial content. More information is available here »

Positive data reported for eptinezumab in Sunrise trial New insights on treatment holidays with erenumab Dual CGRP ligand mAb and gepant therapy reduces headache severity CGRP-mAb switching yields migraine day reduction Lower switching rates with atogepant than CGRP mAbs EMBRACE shows erenumab reduces migraine severity Older patients benefit from CGRP mAbs too DELIVER shows long term QoL benefits with eptinezumab

Sajedeh Eftekhari PhD

Editorial Board

Post Doc

Department of Neurology, David Geffen School of Medicine at UCLA, California, USA

Sajedeh Eftekhari obtained her Bachelor’s degree in Biomedical Science followed by a Master’s degree in Biomedicine in 2007, at Lund University in the field of Ophthalmology. Subsequent to her studies she worked as a Medical Laboratory Scientist at the Department of Transplantation at Lund University Hospital. In 2009, she began her PhD studies at Lund University in the field of migraine research. During this time she also did an internship at the Pain and Migraine Department at Merck.

Her research focuses on the distribution of CGRP and its receptor within the trigeminovascular system and CNS in rodent, primate and human tissue. Her work also aims to explore potential sites of action of drugs inhibiting CGRP signaling. In 2013, she completed her PhD studies and currently she is a Post Doc at the University of California, Los Angeles (UCLA) where she is investigating the functional roles of CGRP and PACAP in the trigeminovascular system and CNS.

« Back to Editorial Board

Educational Partners and Supporters

This program is funded in part via an independent educational grant from AbbVie.

Organon has provided sponsorship towards this independent resource. Organon has had no editorial input or control over content, nor opportunity to influence.

Financial support was provided as GMG Knowledge Gap Grant from Pfizer Inc, Pfizer have provided only financial support and had no input into the content provided.

Editorial PolicyCGRP Forum is an expert resource for clinicians and healthcare professionals working with migraine patients. All patients should discuss their medication with their healthcare professional. Unless otherwise indicated, opinions expressed in the CGRP Education and Research Forum are those of the contributors. Although every effort is made to ensure accuracy and avoid mistakes, no liability on the part of the CGRP Forum, the editors or the editorial board is accepted for the consequences of any misleading or inaccurate information.

© 2024 | Privacy Policy | Editorial Policy | Governance | Disclaimer Statement | Partnership & Outreach | Educational Partners and Supporters |